Global Blood Therapeutics Inc (GBT) Receives Average Recommendation of “Buy” from Analysts

Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) have earned a consensus recommendation of “Buy” from the sixteen research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $65.58.

GBT has been the subject of several research reports. Cantor Fitzgerald set a $61.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Monday, December 11th. HC Wainwright set a $73.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Monday, December 11th. Nomura increased their price target on shares of Global Blood Therapeutics to $91.00 and gave the company a “buy” rating in a research report on Monday, December 11th. BidaskClub upgraded shares of Global Blood Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 12th. Finally, Oppenheimer set a $79.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Tuesday, December 12th.

In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of the stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the completion of the transaction, the insider now owns 140,055 shares in the company, valued at $4,201,650. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Peter Radovich sold 12,500 shares of the stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $35.00, for a total transaction of $437,500.00. Following the transaction, the vice president now owns 2,684 shares of the company’s stock, valued at approximately $93,940. The disclosure for this sale can be found here. Insiders have sold 88,500 shares of company stock valued at $3,003,350 in the last quarter. Company insiders own 5.30% of the company’s stock.

A number of large investors have recently modified their holdings of the business. Perceptive Advisors LLC boosted its position in Global Blood Therapeutics by 8.4% during the third quarter. Perceptive Advisors LLC now owns 4,264,066 shares of the company’s stock worth $132,399,000 after purchasing an additional 330,139 shares during the period. BlackRock Inc. boosted its position in shares of Global Blood Therapeutics by 30.0% in the second quarter. BlackRock Inc. now owns 3,404,538 shares of the company’s stock valued at $93,114,000 after acquiring an additional 785,691 shares during the period. Vanguard Group Inc. boosted its position in shares of Global Blood Therapeutics by 15.7% in the second quarter. Vanguard Group Inc. now owns 2,933,251 shares of the company’s stock valued at $80,224,000 after acquiring an additional 397,271 shares during the period. Orbimed Advisors LLC boosted its position in shares of Global Blood Therapeutics by 10.2% in the third quarter. Orbimed Advisors LLC now owns 2,393,635 shares of the company’s stock valued at $74,322,000 after acquiring an additional 221,700 shares during the period. Finally, State Street Corp boosted its position in shares of Global Blood Therapeutics by 217.9% in the second quarter. State Street Corp now owns 2,138,323 shares of the company’s stock valued at $58,479,000 after acquiring an additional 1,465,595 shares during the period. Hedge funds and other institutional investors own 90.48% of the company’s stock.

Shares of Global Blood Therapeutics (NASDAQ:GBT) traded up $0.55 during mid-day trading on Monday, hitting $36.80. 1,162,668 shares of the stock traded hands, compared to its average volume of 1,041,849. Global Blood Therapeutics has a 52 week low of $13.35 and a 52 week high of $45.85.

Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.04). During the same quarter in the prior year, the firm posted ($0.58) EPS. sell-side analysts expect that Global Blood Therapeutics will post -2.55 EPS for the current year.

WARNING: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/18/global-blood-therapeutics-inc-gbt-receives-average-recommendation-of-buy-from-analysts.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply